FDA has approved Corifact (CSL Behring), the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency.
FDA has approved Corifact (CSL Behring), the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency.
Congenital Factor XIII deficiency affects 1 out of every 3 million to 5 million people in the United States. The deficiency may lead to soft-tissue bruising, mucosal bleeding, and fatal intracranial bleeding. Newborns with Factor XIII deficiency may have umbilical cord bleeding.
“Patients suffering from Factor XIII deficiency have a range of symptom severities and those in emerging markets tend to have fewer options,” Sarah Terry, president, global managing directorat Life Science Analytics, a Datamonitor company, told Formulary.
There have been only slight improvements in treatment options over the years and are no curative therapies on the horizon, added Terry. “Newer products for Factor XIII deficiency focus on the use of second-hand protein-engineering technologies used primarily to improve potency and duration of activity,” she said. “However, the cost of management is still a significant challenge for many patients. And, with any new product, it will be important to see if the cost of treatment is reduced so that greater patient access could ensue.”
FDA approved Corifact based on results of a clinical study of 14 people, including children, with congenital Factor XIII deficiency. The most common side effects observed were hypersensitivity reactions (allergy, rash, pruritus, and erythema), chills, fever, arthralgia, headache, elevated thrombin-antithrombin levels, and an increase in liver enzymes.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More